These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35503561)

  • 1. Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice.
    Wu ML; Liu FL; Sun J; Li X; Qin JR; Yan QH; Jin X; Chen XW; Zheng YT; Zhao JC; Wang JH
    Zool Res; 2022 May; 43(3):457-468. PubMed ID: 35503561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
    Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
    Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury.
    Wu ML; Liu FL; Sun J; Li X; He XY; Zheng HY; Zhou YH; Yan Q; Chen L; Yu GY; Chang J; Jin X; Zhao J; Chen XW; Zheng YT; Wang JH
    Signal Transduct Target Ther; 2021 Dec; 6(1):428. PubMed ID: 34921131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast cell degranulation-triggered by SARS-CoV-2 induces tracheal-bronchial epithelial inflammation and injury.
    Cao JB; Zhu ST; Huang XS; Wang XY; Wu ML; Li X; Liu FL; Chen L; Zheng YT; Wang JH
    Virol Sin; 2024 Apr; 39(2):309-318. PubMed ID: 38458399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.
    Contini C; Enrica Gallenga C; Neri G; Maritati M; Conti P
    Med Hypotheses; 2020 Nov; 144():109876. PubMed ID: 32562915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
    Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M
    Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
    Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
    Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
    Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.
    Jang Y; Shin JS; Lee MK; Jung E; An T; Kim UI; Kim K; Kim M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes.
    Bojkova D; Wagner JUG; Shumliakivska M; Aslan GS; Saleem U; Hansen A; Luxán G; Günther S; Pham MD; Krishnan J; Harter PN; Ermel UH; Frangakis AS; Milting H; Zeiher AM; Klingel K; Cinatl J; Dendorfer A; Eschenhagen T; Tschöpe C; Ciesek S; Dimmeler S
    Cardiovasc Res; 2020 Dec; 116(14):2207-2215. PubMed ID: 32966582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
    Jung LS; Gund TM; Narayan M
    Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.
    Moreno S; Alcázar B; Dueñas C; González Del Castillo J; Olalla J; Antela A
    Drug Des Devel Ther; 2022; 16():827-841. PubMed ID: 35370401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
    de Wit E; Feldmann F; Cronin J; Jordan R; Okumura A; Thomas T; Scott D; Cihlar T; Feldmann H
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6771-6776. PubMed ID: 32054787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY
    Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2.
    Nayeem SM; Sohail EM; Sudhir GP; Reddy MS
    Eur J Pharmacol; 2021 Jan; 890():173642. PubMed ID: 33065096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic.
    Taha HR; Keewan N; Slati F; Al-Sawalha NA
    Pharmacology; 2021; 106(9-10):462-468. PubMed ID: 34515227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.